WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 51'2101 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 47'1311 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 16'802  16'759  16'714  16'666  16'615  15'860  14'890  14'087 
Births 179  179  180  181  182  198  190  171 
Surviving infants 179  179  179  180  182  197  189  170 
Pop. less than 5 years 897  888  882  891  919  983  927  882 
Pop. less than 15 years 2'853  2'864  2'870  2'882  2'908  2'944  2'715  3'183 
Female 15-49 years 3'731  3'765  3'800  3'830  3'853  3'953  3'957  3'539 

Number of reported case

(Click for retrospective incidence data for Netherlands (the))
Diphtheria
Japanese encephalitis
Measles 140  2'632  10  51  15  1'019  16  178 
Mumps 39  204  398  610  562 
Pertussis 8'960  2'858  13'552  6'726  2'912  4'836  471  30 
Polio*
Rubella 58  12 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Netherlands (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          96  97  97  97  97  97  97  96 
DTP4          95 
IPV1         
HepB_BD          99  99  99  98 
HepB3          94  95 
Hib3          96  97  97  97  97  96 
JapEnc         
MCV1          96  96  96  96  96  96  94  91 
MCV2          93  92  93  93  92 
PCV1         
PCV3          95  96  96  96  96 
Pol3          96  97  97  97  97  97  97  96 
Rota1         
Rota_last         
Rubella1          96  96  96  96  96 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Netherlands (the))
DTP1 98  99  99  99  99  99  98  98 
DTP3 96  97  97  97  97  97  97  96 
HepB3 95  31 
HepB_BD
Hib3 96  97  97  97  97  96 
MCV1 96  96  96  96  96  96  94  91 
MCV2 93  92  93  93  92 
PCV3 95  96  96  96  96 
Pol3 96  97  97  97  97  97  97  96 
Rota_last

Number of districts in the country 393  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 92
From 80 to 89% 6
From 50 to 79% 2
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTIPV 9 years; Yes
DTaPHibHepIPV 2, 3, 4, 11 months; Yes
DTaPIPV 4 years; Yes
HPV 12 years, + 6month; Yes
HepB <48 hrs after birth; Yes children of carrier mothers; immigrants from endemic coutries(at contact, +1, +6 months)
HepB_Adult 1st contact; +1, +6 months; Yes
HepB_Pediatric < 48 hours; Yes children of carrier mothers
Influenza_Adult >= 60 years; Yes and health care workers, adults with chronic diseases, and other risk groups
Influenza_Pediatric children with chronic diseases
MMR 14 months; 9 years; Yes
MenC_conj 14 months; Yes
Pneumo_conj 2, 4, 11 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number  

System performance

Total Nº districts in country number 393  403  408  415  12  12   
Nº districts with DTP3 coverage >=80% number 385  394  400  406 
% of districts with DTP3 coverage >=80% From 0 to 100% 98  98  98  98   
Nº districts with measles (MCV1) coverage >=95% number 283  317  331  329       
% of districts with MCV1 coverage >=95% From 0 to 100% 72  79  81  79       

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  No  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.